Surprisingly Useful AI Article Enhancements
Hancock Prospecting has made an initial US$50 million investment in Lumitron Technologies, the California-based company developing compact X-ray imaging and electron beam radiotherapy systems for use in cancer treatment, mining and industrial inspection.
The deal includes the right for Hancock to increase its investment to US$100 million during the 2026 calendar year. Hancock has nominated a representative to the Lumitron board and placed two members on the company’s technical review committee.
As part of the agreement, Hancock has secured the right to bring three of Lumitron’s HyperVIEW systems to Australia, which would be the first deployments of the technology in the country.
What Lumitron Has Built
Lumitron’s HyperVIEW platform combines advanced X-ray imaging with Very High Energy Electron (VHEE) beam radiotherapy capability in a compact system designed to fit within existing clinical environments.
The underlying technology is based on patented laser-Compton physics originally developed at the Lawrence Livermore National Laboratory in the United States. Lumitron holds exclusive commercialisation rights to the core intellectual property, comprising a licensed patent portfolio spanning more than 14 patent families.
Dr Glenn Rice, a biophysics and oncology drug-development expert serving on Lumitron’s technical review committee, described the platform as a departure from existing clinical technology.
“Lumitron represents the first fundamental change in clinical radiotherapy in 70 years, and the first fundamental change in clinical and industrial X-ray radiography in 130 years,” Dr Rice stated.
Dr Rice is the former COO and President of Pharmacyclics and has held roles at Stanford Research Institute and Genentech.
Imaging And Treatment Claims
Lumitron claims its HyperVIEW technology can deliver between 100 and 1,000 times greater imaging resolution than conventionally produced X-ray systems, with up to 100 times lower radiation dose.
The US Food and Drug Administration has granted Breakthrough Device Designation to Lumitron’s HyperVIEW breast cancer imaging technology. Studies published in the peer-reviewed journal Medical Physics demonstrated imaging performance improvements of more than 3,000 per cent across breast cancer imaging metrics compared with existing clinical systems, according to the company. The imaging approach does not require breast compression.
Dr Rice noted that additional peer-reviewed research published in Frontiers in Physics demonstrated records in laser-Compton X-ray output, high-resolution X-ray imaging capability and VHEE FLASH radiotherapy capabilities achieved through the platform.
The VHEE beam radiotherapy capability is designed to deliver localised radiation treatment rapidly while reducing damage to healthy tissue. However, a commercially focused VHEE FLASH radiotherapy machine does not yet exist. Hancock’s investment will support Lumitron in developing its first such machine.
Why Hancock Is Investing
Gina Rinehart’s Hancock Prospecting has interests spanning iron ore, agriculture, critical minerals, energy and retail. The Lumitron investment represents a move into medical and industrial technology.
Rinehart framed the investment around both healthcare and mining applications.
“In healthcare, HyperVIEW has been developed for advanced medical imaging and precision radiotherapy applications designed to improve the speed and accuracy of cancer detection and treatment,” Mrs Rinehart explained. “Hancock Prospecting’s investment will support Lumitron to develop its first commercially focused VHEE FLASH radiotherapy machine, a capability that does not currently exist for commercial use.”
Related: Best Business Laptops for work & school
Related: Best Gaming Laptops
Related: Best Portable Laptop
On the mining side, Rinehart pointed to HyperVIEW’s potential to go beyond conventional industrial X-ray systems, which are typically limited to analysing the shape and density of materials.
“HyperVIEW has the potential to identify the composition and concentration of minerals and contaminants in ore, allowing mining operators to selectively process higher-value ore, thereby improving recovery rates while potentially reducing energy consumption and overall processing costs.”
Rinehart also highlighted the company’s engagement with US government and research organisations, including the United States Department of Energy, the Defence Advanced Research Projects Agency (DARPA), the University of California, Irvine and Australia’s I-MED Radiology Network.
“I am especially excited about the potential to help patients in Australia and overseas who are suffering from up to stage 4 cancer, after the equipment has been approved for use in Australia. Which I sincerely hope will not be delayed,” Mrs Rinehart added.
Lumitron’s Technology Development
Dr Chris Barty, Co-Founder, Executive Director and Chief Technology Officer of Lumitron Technologies, described a near-decade of development work behind the platform.
“We have developed unique laser and accelerator hardware capable of delivering X-ray and electron beam performance from a compact platform architecture,” Dr Barty outlined. “These are capabilities that have historically not been commercially available in deployable systems and have the potential to impact medicine, industry and scientific research.”
Dr Rice added that in advanced manufacturing and 3D additive manufacturing applications, HyperVIEW is designed to detect microscopic structural defects at scales as small as one twentieth the width of a human hair in real time, supporting quality assurance and material analysis.
The Road To Commercialisation
Maurie Stang, Co-Founder and Executive Chairman of Lumitron Technologies, described the Hancock investment as a step in the company’s transition from development into commercial deployment.
“Hancock Prospecting joins our investor base supporting the company’s transition from advanced development into commercial scale-up,” Stang commented. “Capabilities traditionally associated with large-scale research infrastructure are now being developed in a platform designed for broader clinical and industrial deployment.”
Stang pointed to long-term opportunities across healthcare, mining and advanced manufacturing as demand grows for more precise imaging, treatment, analysis and assay capability.
The company is headquartered in Irvine, California, with investor and commercial engagement in Australia and the United States. Lumitron was co-founded by Stang and Dr Barty, who invented the core laser-based technologies underpinning the HyperVIEW platform.
Australian Deployment
The three HyperVIEW systems that Hancock has secured the right to bring to Australia would represent the first deployment of the technology in the country. However, the systems will need regulatory approval before clinical use in Australia can begin.
Professor Ian Plimer, who is joining Lumitron’s technical review committee, highlighted Mrs Rinehart’s history of involvement in breast cancer awareness, including establishing what the company describes as Australia’s first dedicated breast cancer foundation and the nation’s first National Breast Cancer Day in the early 1990s.
“We believe HyperVIEW represents a potentially generational advancement in imaging and radiotherapy capability, with the potential to support earlier detection, more precise treatment and better patient outcomes,” Prof Plimer noted.
“This investment will support and ensure the future rollout of advanced imaging and radiotherapy capability across Australia.”
What Remains To Be Proven
While Lumitron’s peer-reviewed publications and the FDA’s Breakthrough Device Designation lend credibility to the technology’s potential, several steps remain before the platform reaches widespread clinical and industrial use.
The VHEE FLASH radiotherapy machine is yet to be built in a commercially focused configuration. Regulatory approval in Australia has not been secured. And the mining and manufacturing applications, while described as promising by the company, are still in development.
The scale of Hancock’s commitment – up to US$100 million in 2026 alone – signals confidence in the platform’s commercial trajectory, but the path from laboratory-proven physics to deployed clinical and industrial systems at scale typically involves extended development, regulatory and certification timelines.
Last Updated on June 26, 2026 by Nick Ross
